Study of a blood- and tissue-based index in large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a “Mixed Molecular Clinical Index” (MMCI), which combines test results from lymphoma tissue and clinical information. It aims to help better understand how diffuse large B-cell lymphoma behaves and how patients may respond to standard first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of high-grade diffuse large B-cell lymphoma (DLBCL) and are starting the first standard treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
This study looks at how changes in the MYC gene affect the outlook for people with certain fast-growing lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma. It aims to better understand the tumor environment and how these patients respond to standard chemotherapy.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial studies tissue samples from people with MALT lymphoma (a type of low-grade lymphoma) to learn more about its biology. It aims to improve understanding of the disease, which could help future treatments.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.